Mortality No Higher in Patients with Well-Controlled HIV than in the General Population

Data from two large clinical trials revealed no elevated risk for death among patients on continuous ART with undetectable HIV levels and high CD4-cell counts.

The success of antiretroviral therapy (ART) leads to interesting questions about the long-term health of HIV-infected patients who are doing well on ART relative to that of uninfected individuals. To explore this issue, investigators assessed mortality in non–injection drug users drawn from the continuous ART control arms of the ESPRIT and SMART trials. Patients were included in the analysis if they had both suppressed viral loads and CD4-cell counts >350 cells/mm³ at any time during the preceding 6 months. Standardized mortality ratios (SMRs) were calculated by comparing death rates in the study population with general population death rates obtained from the Human Mortality Database.

Among 3280 participants (median age, 43; 80% male), 62 d…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Mortality No Higher in Patients with Well-Controlled HIV than in the General Population

Topics

Reviewing Author